Advertisement

Predictive factors for acute thrombogenesis occurring immediately after bypass procedure for moyamoya disease

  • Takeshi MikamiEmail author
  • Hime Suzuki
  • Ryo Ukai
  • Katsuya Komatsu
  • Yukinori Akiyama
  • Masahiko Wanibuchi
  • Kiyohiro Houkin
  • Nobuhiro Mikuni
Original Article

Abstract

Extracranial-to-intracranial (EC-IC) bypass surgery is an effective treatment for patients with moyamoya disease and other conditions. Some patients with moyamoya disease have a risk of acute thrombogenesis at the anastomotic site just after bypass surgery. The purpose of this study was to study risk factors of acute thrombogenesis and determine effective countermeasures. This study included 48 patients (66 EC-IC bypass procedures) with moyamoya disease and 52 controls (54 procedures) without moyamoya disease. The development of acute thrombogenesis was compared between the moyamoya disease and control groups. In the moyamoya disease group, clinical and radiological characteristics were assessed with respect to acute thrombogenesis. In the patients with acute thrombogenesis, causes of technical problems were retrospectively examined. The incidence of acute thrombogenesis was significantly higher in the moyamoya disease group than those in the control group. In the moyamoya disease group, acute thrombogenesis was observed in seven patients. In the moyamoya disease group, the magnetic resonance angiography (MRA) scores were significantly higher in patients with acute thrombogenesis than those in the patients without acute thrombogenesis. In the multivariate analysis, the predictive factor of acute thrombogenesis in moyamoya disease was a high MRA score (odds ratio, 2.336; p = 0.009). During EC-IC bypass surgery for moyamoya disease, acute thrombogenesis should be considered to obtain a high patency rate, particularly in patients with high MRA scores. Acute thrombogenesis will not influence morbidity if proper countermeasures are followed; therefore, the prediction and recognition of white thrombus are important for a successful bypass surgery.

Keywords

Moyamoya disease Bypass Thrombogenesis Complication 

Notes

Funding information

No funding was received for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

We declare that this study has been approved by the Ethics Committee of the Sapporo Medical University Hospital (no. 282-166) and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All the patients provided informed consent before participation.

References

  1. 1.
    Chaves CJ, Caplan LR (2000) Heparin and oral anticoagulants in the treatment of brain ischemia. J Neurol Sci 173:3–9CrossRefPubMedGoogle Scholar
  2. 2.
    Czabanka M, Vajkoczy P, Schmiedek P, Horn P (2009) Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population. Neurosurg Focus 26:E9.  https://doi.org/10.3171/2009.1.focus08298 CrossRefPubMedGoogle Scholar
  3. 3.
    Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, Cao Y, Zhao Y, Pan Y, Ye X, Liu X, Zhang Q, Wang J, Yang Z, Zhao M, Zhao J (2018) Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study. J Neurosurg 128:1327–1337.  https://doi.org/10.3171/2016.12.jns162626 CrossRefPubMedGoogle Scholar
  4. 4.
    Diamond SL (2016) Systems analysis of thrombus formation. Circ Res 118:1348–1362.  https://doi.org/10.1161/circresaha.115.306824 CrossRefPubMedGoogle Scholar
  5. 5.
    Fujimura M, Inoue T, Shimizu H, Saito A, Mugikura S, Tominaga T (2012) Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease. Cerebrovasc Dis (Basel, Switzerland) 33:436–445.  https://doi.org/10.1159/000336765 CrossRefGoogle Scholar
  6. 6.
    Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S (2018) Angiographic features of hemorrhagic moyamoya disease with high recurrence risk: a supplementary analysis of the Japan Adult Moyamoya Trial. J Neurosurg 128:777–784.  https://doi.org/10.3171/2016.11.jns161650 CrossRefPubMedGoogle Scholar
  7. 7.
    Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359:938–949.  https://doi.org/10.1056/NEJMra0801082 CrossRefPubMedGoogle Scholar
  8. 8.
    Gu Y, Ni W, Jiang H, Ning G, Xu B, Tian Y, Xu F, Liao Y, Song D, Mao Y (2012) Efficacy of extracranial-intracranial revascularization for non-moyamoya steno-occlusive cerebrovascular disease in a series of 66 patients. J Clin Neurosci 19:1408–1415.  https://doi.org/10.1016/j.jocn.2011.11.037 CrossRefPubMedGoogle Scholar
  9. 9.
    Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM, Marks MP, Steinberg GK (2009) Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article. J Neurosurg 111:927–935.  https://doi.org/10.3171/2009.4.jns081649 CrossRefPubMedGoogle Scholar
  10. 10.
    Han JS, Abou-Hamden A, Mandell DM, Poublanc J, Crawley AP, Fisher JA, Mikulis DJ, Tymianski M (2011) Impact of extracranial-intracranial bypass on cerebrovascular reactivity and clinical outcome in patients with symptomatic moyamoya vasculopathy. Stroke 42:3047–3054.  https://doi.org/10.1161/strokeaha.111.615955 CrossRefPubMedGoogle Scholar
  11. 11.
    Heemskerk JW, Mattheij NJ, Cosemans JM (2013) Platelet-based coagulation: different populations, different functions. J Thromb Haemost 11:2–16.  https://doi.org/10.1111/jth.12045 CrossRefPubMedGoogle Scholar
  12. 12.
    Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T (2005) Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovasc Dis (Basel, Switzerland) 20:347–354.  https://doi.org/10.1159/000087935 CrossRefGoogle Scholar
  13. 13.
    Irikura K, Miyasaka Y, Kurata A, Tanaka R, Fujii K, Yada K, Kan S (1996) A source of haemorrhage in adult patients with moyamoya disease: the significance of tributaries from the choroidal artery. Acta Neurochir 138:1282–1286CrossRefPubMedGoogle Scholar
  14. 14.
    Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW (2018) Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg 128:793–799.  https://doi.org/10.3171/2016.11.jns161688 CrossRefPubMedGoogle Scholar
  15. 15.
    Jerjes-Sanchez C (2005) Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J 26:3–4.  https://doi.org/10.1093/eurheartj/ehi041 CrossRefPubMedGoogle Scholar
  16. 16.
    Jussen D, Horn P, Vajkoczy P (2013) Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery. Cerebrovasc Dis (Basel, Switzerland) 35:355–362.  https://doi.org/10.1159/000348649 CrossRefGoogle Scholar
  17. 17.
    Kazumata K, Ito M, Tokairin K, Ito Y, Houkin K, Nakayama N, Kuroda S, Ishikawa T, Kamiyama H (2014) The frequency of postoperative stroke in moyamoya disease following combined revascularization: a single-university series and systematic review. J Neurosurg 121:432–440.  https://doi.org/10.3171/2014.1.jns13946 CrossRefPubMedGoogle Scholar
  18. 18.
    Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, Hwang YS, Kim IO, Lee DS, Lee J, Wang KC (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68:92–101.  https://doi.org/10.1002/ana.21981 CrossRefPubMedGoogle Scholar
  19. 19.
    Komatsu K, Mikami T, Noshiro S, Miyata K, Wanibuchi M, Mikuni N (2016) Reversibility of white matter hyperintensity by revascularization surgery in moyamoya disease. J Stroke Cerebrovasc Dis 25:1495–1502.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.02.035 CrossRefPubMedGoogle Scholar
  20. 20.
    Komura S, Mikami T, Sugino T, Suzuki Y, Komatsu K, Wanibuchi M, Mikuni N (2017) Complementary relation between direct and indirect bypass in progress of collateral circulation in moyamoya disease. World Neurosurg 104:197–204.  https://doi.org/10.1016/j.wneu.2017.04.122 CrossRefPubMedGoogle Scholar
  21. 21.
    Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056–1066.  https://doi.org/10.1016/s1474-4422(08)70240-0 CrossRefPubMedGoogle Scholar
  22. 22.
    Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC (2014) Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45:1415–1421.  https://doi.org/10.1161/strokeaha.113.004386 CrossRefPubMedGoogle Scholar
  23. 23.
    Mizoi K, Kayama T, Yoshimoto T, Nagamine Y (1996) Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients? Surg Neurol 45:541–548 discussion 548-549CrossRefPubMedGoogle Scholar
  24. 24.
    Nishimoto A, Takeuchi S (1968) Abnormal cerebrovascular network related to the internal cartoid arteries. J Neurosurg 29:255–260.  https://doi.org/10.3171/jns.1968.29.3.0255 CrossRefPubMedGoogle Scholar
  25. 25.
    Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K (2016) Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open 6:e009942.  https://doi.org/10.1136/bmjopen-2015-009942 CrossRefPubMedGoogle Scholar
  26. 26.
    Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis (2012) Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir 52:245–266CrossRefGoogle Scholar
  27. 27.
    Sasagawa A, Mikami T, Hirano T, Akiyama Y, Mikuni N (2018) Characteristics of cerebral hemodynamics assessed by CT perfusion in moyamoya disease. J Clin Neurosci 47:183–189.  https://doi.org/10.1016/j.jocn.2017.09.020 CrossRefPubMedGoogle Scholar
  28. 28.
    Schubert GA, Biermann P, Weiss C, Seiz M, Vajkoczy P, Schmiedek P, Thome C (2014) Risk profile in extracranial/intracranial bypass surgery—the role of antiplatelet agents, disease pathology, and surgical technique in 168 direct revascularization procedures. World Neurosurg 82:672–677.  https://doi.org/10.1016/j.wneu.2013.06.010 CrossRefPubMedGoogle Scholar
  29. 29.
    Suzuki J, Takaku A (1969) Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288–299CrossRefPubMedGoogle Scholar
  30. 30.
    Suzuki H, Mikami T, Komatsu K, Noshiro S, Miyata K, Hirano T, Wanibuchi M, Mikuni N (2017) Assessment of the cortical artery using computed tomography angiography for bypass surgery in moyamoya disease. Neurosurg Rev 40:299–307.  https://doi.org/10.1007/s10143-016-0773-0 CrossRefPubMedGoogle Scholar
  31. 31.
    Zhao Y, Zhang Q, Zhang D, Zhao Y (2017) Effect of aspirin in postoperative management of adult ischemic moyamoya disease. World Neurosurg 105:728–731.  https://doi.org/10.1016/j.wneu.2017.06.057 CrossRefPubMedGoogle Scholar
  32. 32.
    Zhao M, Deng X, Zhang D, Wang S, Zhang Y, Wang R, Zhao J (2018) Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease. J Neurosurg:1–12.  https://doi.org/10.3171/2017.10.jns171749

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurosurgerySapporo Medical UniversitySapporoJapan
  2. 2.Department of NeurosurgeryHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations